China Biotech Services Holdings Limited reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was HKD 18.36 million compared to HKD 588.84 million a year ago. Net loss was HKD 35.49 million compared to net income of HKD 91.3 million a year ago. Basic loss per share from continuing operations was HKD 0.037 compared to basic earnings per share from continuing operations of HKD 0.095 a year ago.
For the nine months, sales was HKD 200.71 million compared to HKD 1,275.75 million a year ago. Net loss was HKD 65.98 million compared to net income of HKD 159.52 million a year ago. Basic loss per share from continuing operations was HKD 0.068 compared to basic earnings per share from continuing operations of HKD 0.166 a year ago.